Table 3. Association analysis of rs1805812 x rs607974 interactions between MRE11A and NBS1 with the risk of NHL.
| NBS1 (rs1805812)/ | Stage 1 | Stage 2 | Stage 1 & 2 [Aggregate] | |||||||||
| MRE11A (rs607974) genotype | Cases | Controls | OR (95% CI) | Cases | Controls | OR (95% CI) | Cases | Controls | OR (95% CI) | |||
| Model 1 | ||||||||||||
| NBS1 TT/MRE11A GG | 167 | 333 | 1.0 (Ref) | 241 | 362 | 1.0 (Ref) | 408 | 695 | 1.0 (Ref) | |||
| NBS1 TT/MRE11A AG,AA; NBS1 CT,CC/MRE11A GG | 213 | 347 | 1.22 (0.95–1.58) | 208 | 336 | 0.93 (0.73–1.18) | 421 | 683 | 1.05 (0.88–1.25) | |||
| NBS1 CT,CC/MRE11A AG,AA | 9 | 38 | 0.47 (0.22–1.00) | 12 | 42 | 0.43 (0.22–0.83) | 21 | 80 | 0.45 (0.27–0.73) | |||
| P for interaction | 0.8713 | 0.03153 | 0.07991 | |||||||||
| Model 2 | ||||||||||||
| NBS1 TT, CT/MRE11A GG, AG | 354 | 656 | 1.0 (Ref) | 435 | 697 | 1.0 (Ref) | 789 | 1353 | 1.0 (Ref) | |||
| NBS1 CC/MRE11A GG,AG,AA; NBS1 TT,CT/MRE11A AA | 35 | 62 | 1.05 (0.68–1.61) | 26 | 43 | 0.97 (0.59–1.6) | 61 | 105 | 1 (0.72–1.38) | |||
| P for interaction | 0.4434 | 0.6881 | 0.9218 | |||||||||
| Model 3 | ||||||||||||
| NBS1 TT,CT,CC/MRE11A GG; NBS1 TT/MRE11A AG,AA | 380 | 680 | 1.0 (Ref) | 449 | 698 | 1.0 (Ref) | 829 | 1378 | 1.0 (Ref) | |||
| NBS1 CT,CC/MRE11A AG,AA | 9 | 38 | 0.42 (0.2–0.89) | 12 | 42 | 0.44 (0.23–0.85) | 21 | 80 | 0.44 (0.27–0.71) | |||
| P for interaction | 0.002537 | 0.002361 | 0.0000209 | |||||||||
OR = odds ratio; CI = confidence interval.